A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients With Solid Tumors

Trial Profile

A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Larotrectinib (Primary)
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Loxo Oncology
  • Most Recent Events

    • 06 Jun 2017 Results (data cut off: 31 Jan 2017, n=55) from NCT02122913, NCT02637687 and NCT02576431 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 03 Jun 2017 According to a Loxo Oncology media release, the results of this trial and 2 other trials will serve as the basis for the larotrectinib New Drug Application (NDA), which the company expects to submit in late 2017 or early 2018 to the US FDA.
    • 03 Jun 2017 Combined interim data from this and two other trials was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017, according to a Loxo Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top